New hope for amyloidosis patients: Long-Term safety study of AT-02 underway

NCT ID NCT05951049

Ongoing Disease control Sponsor: Attralus, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with systemic amyloidosis, a disease where abnormal proteins build up in organs. It tests the long-term safety of an experimental drug called AT-02. About 120 adults will receive the drug and be monitored for side effects and how the drug behaves in the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOIDOSIS; SYSTEMIC

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Kansas City

Kansas City, Kansas, 64111, United States
OHSU (Oregon Health & Science University)

Portland, Oregon, 97239, United States
Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.